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Summary 1 
 2 
Alkaptonuria is a rare metabolic disease leading to systemic changes including early and severe 3 
arthropathy which affects mobility. For unknown reasons, the onset of degenerative changes is 4 
delayed to around 30 years of age when both objective and subjective symptoms develop. In order to 5 
complement description of the structural changes in alkaptonuria with measures of movement 6 
function, clinical gait analysis was added to the list of assessments in 2013. The aim of this study was 7 
to describe the deviation of gait from normality as a function of age in patients with alkaptonuria. 8 
Three-dimensional movement of reflective markers attached to joints were captured during walking 9 
in 39 patients and 10 controls. Subsequent to processing the data to emphasise the shape of marker 10 
trajectories, the mean Movement Deviation Profile was generated for all participants. This single 11 
number measure gives the deviation of a patient’s gait from a distributed definition of gait normality. 12 
Results showed that gait deviation roughly follows a sigmoid profile with minimal increase of gait 13 
deviations in a younger patient group and an abrupt large increase around the second half of the 4th 14 
decade of life. Larger variations of gait deviations were found in the older group than in the younger 15 
group suggesting a complex interaction of multiple factors which determine gait function after 16 
symptoms manifest. Continued gait analysis of adults with AKU, extended to younger adults and 17 
children with AKU, is expected to complete understanding of both the natural history of alkaptonuria 18 
and how interventions can affect movement function. 19 
 20 
 21 
Take-home message 22 
 23 
Deviation of gait from normality shows an abrupt increase in the second half of the 4th decade of life 24 
in alkaptonuria. 25 
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Introduction 1 
 2 
Alkaptonuria (OMIM #203500) is an ultra-rare autosomal recessive metabolic disease with an 3 
estimated incidence of 1:250,000-1:1,000,000 in the US (Introne and Gahl, 2013). A defect of 4 
homogentisate 1,2-dioxygenase (EC 1.13.11.5) blocks the catabolism of phenylalanine and tyrosine 5 
resulting in elevated levels of homogentisic acid. After its oxidation, a melanin-like polymer is 6 
produced which binds to virtually all fibrous connective tissues including cartilage, leading to 7 
ochronosis (Ranganath et al. 2013). While alkaptonuria begins at conception, there is only anecdotal 8 
evidence of joint pain in younger patients followed by a rapid increase of symptoms around 30 years 9 
of age (Introne and Gahl, 2013; Ranganath and Cox, 2011). Among various degenerative changes 10 
affecting the cardiovascular and renal systems, a characteristic of the disease is early and severe 11 
arthropathy (Abimbola et al. 2011; Aquaron, 2013). Despite mounting information about structural 12 
changes in alkaptonuria, little is known about the functional effects of arthritic changes on movement. 13 
A prospective randomised clinical trial showed that nitisinone reduced homogentisic acid levels by 14 
95%, but the total hip range of motion, spinal flexion, functional reach, timed get up and go, and 6-15 
minute walk test did not improve (Introne et al. 2011). In order to better understand how movement 16 
degenerates in alkaptonuria, in 2013 we started performing gait analysis on adults who visit the 17 
National Alkaptonuria Centre in Liverpool. 18 
 19 
Gait analysis is a routine non-invasive procedure which allows the collection of objective and 20 
quantitative information in order to identify abnormalities, postulate their causes and propose 21 
treatments for those with walking problems (Davis et al. 2004). Body segment motion is captured by 22 
infrared cameras which track reflective markers attached to the legs and pelvis, and ground reaction 23 
forces are recorded by force platforms embedded in a walkway over which the participant walks. 24 
Dynamic joint angles, moments and powers are calculated in all anatomical planes over several strides. 25 
Interpretation of the results by gait analysts can uncover reasons for gait changes, allowing specific 26 
anatomical structures to be targeted for interventions.  27 
 28 
The traditional interpretation of gait results has recently been complemented by the successful 29 
derivation of simplified measures of gait deviation, often represented by a single number. Notable 30 
and widely used examples are the Gait Deviation Index (GDI, Schwartz and Rozumalski, 2008) and the 31 
Gait Profile Score (GPS, Baker et al. 2009). The Movement Deviation Profile (MDP, Barton et al. 2012; 32 
Barton et al. 2015) is a single curve generated by an artificial neural network model which shows 33 
quantitatively how much a patient’s gait deviates from normal gait. A summary measure of the MDP, 34 
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the MDPmean, has demonstrated advantages over the GDI and GPS while showing good agreement 1 
with the GDI (Barton et al. 2012). The MDPmean offers a simple and effective means of quantitatively 2 
describing disease progression in alkaptonuria. The aim of this study was to examine the development 3 
of gait deviations in a cross-sectional sample of adults with alkaptonuria with a view to employing our 4 
method of objective assessment of gait function to monitor disease progression and responses to 5 
treatment. 6 
 7 
 8 
Participants and Methods 9 
 10 
A group of 40 patients with alkaptonuria (AKU) and 10 unimpaired controls underwent clinical gait 11 
analysis at Liverpool John Moores University between May 2013 and October 2014. One patient 12 
refused consent for the use of their data in the following analysis. Thirty-two of the patients were 13 
receiving 2 mg/day nitisinone treatment (13 of them started treatment within 3 days of testing) which 14 
is expected to slow progression of the disease, but not to reverse the effects. Eighteen of the patients 15 
had had one or more joints replaced. Table 1 shows descriptive statistics together with duration of 16 
nitisinone treatment and any joint replacements. 17 
 18 
 19 
Table 1: Characteristics of patients with alkaptonuria (AKU) and unimpaired controls. 20 
 AKU Controls 
N 39 10 
Male/female 23/16 4/6 
Age* (years) 24.5 (12.7) 34.2 (13.1) 
Height* (m) 1.66 (0.10) 1.66 (0.08) 
Mass* (kg) 74.1 (18.2) 69.5 (11.6) 
Body Mass Index* (kg/m2) 26.8 (5.4) 24.3 (4.7) 
Nitisinone use   
On nitisinone for 1 year 19 n/a 
On nitisinone for 1-3 days+ 13 n/a 
No nitisinone treatment 7 n/a 
Joint Replacement   
Knee or hip 14 n/a 
Knee only 9 n/a 
Knee and hip 5 n/a 
Other 6 n/a 
*mean (standard deviation);  +not included in “Nitisinone” group;  n/a: not applicable 21 
 22 
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The gait analysis procedure followed the guidelines of the Clinical Movement Analysis Society of UK 1 
and Ireland. Fifteen reflective markers were attached to the skin or tight fitting clothes over the feet, 2 
lower legs, thighs and the pelvis according to the Helen-Hayes model (Davis et al. 1991). Several walks 3 
were performed at self-selected speed on a 10 m long walkway while the 3D coordinates of markers 4 
were captured by a 10 camera Qualisys Oqus or 16 camera Vicon T10/T160 motion capture system. 5 
The first three clean walks (without marker dropouts or measurement artefacts) of each patient and 6 
the first two walks of each control were selected for analysis. 7 
 8 
The MDP (together with the GDI and GPS) was validated using three-dimensional joint angles but there 9 
is no universally accepted way to describe spatial joint angles given the mathematically equivalent but 10 
effectively very different 16 Euler rotation sequences (Baker 2006; Lees et al. 2010). To circumvent 11 
the uncertainties attached to selecting one particular Euler rotation sequence over others without 12 
clear justification, we used marker positions directly to describe movement as suggested by Federolf 13 
et al. (2013). Marker coordinates attached to body segments are used to calculate joint angles and so 14 
the information contained in 3D angles is also contained in marker coordinates. 15 
 16 
Processing of the X, Y and Z coordinates of the 15 markers involved subtraction of each marker from 17 
a calculated straight line fitted onto the progression of the centre of the pelvis during one gait cycle 18 
(means of the X, Y and Z coordinates of the two ASIS markers and the sacrum marker), followed by 19 
subtracting its mean from each of the X, Y and Z coordinates of the 15 markers and division by their 20 
respective standard deviation. The mean correction and normalisation to unit standard deviation 21 
equalised the differences between the different amplitudes of markers attached to proximal and distal 22 
segments, thereby placing the emphasis on the shape of the marker trajectories as opposed to their 23 
amplitudes. 24 
 25 
The processed marker coordinate data (X, Y and Z of 15 markers) was resampled to 101 values over 26 
one gait cycle and then concatenated into a single column with 3x15x101=4545 rows. Repeated gait 27 
cycles of each participant (2 for controls and 3 for patients) were then added as further columns, giving 28 
two sets of numerical data, one for controls and one for patients. A model of normal gait was created 29 
by passing the data of controls to the self-organising neural network for training in the MDP freeware 30 
program (Barton et al. 2012). MDPmean values for the patients were then derived by the program using 31 
the trained neural network model, and processed further in MATLAB. 32 
 33 
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To summarise, the mean deviation from normal for each patient and control was calculated by 1 
averaging the MDPmean values from the three walks of patients and two walks of controls, and plotted 2 
against age.  As there was considerable scatter in the data, explorative median filtering was applied in 3 
order to investigate the possibility of a transitional increase in deviation from normal gait over a small 4 
age range. Median filters, under the right circumstances, preserve transitions better than more 5 
common linear filters (Huang and Lee, 2006). 6 
 7 
 8 
Results 9 
 10 
Preliminary examination of the values of MDPmean plotted against age (Figure 1) showed that they 11 
increase significantly with age, however, the linear association is not particularly strong (p = 0.005, R2 12 
= 0.193). Further examination suggested that there might be an abrupt change around ages 35-40. 13 
This pattern becomes more obvious when overlaying the series of median filtered data (with filter 14 
points ranging between 5-9) which suggests a sigmoid profile. The upper half of the relationship 15 
(above 35-40 years) showed more variability than the lower half (under 35-40 years). 16 
 17 
 18 
Figure 1: Deviation of gait from normality (MDPmean) as a function of age in patients with 19 
alkaptonuria (AKU) compared to unimpaired controls (individuals and their mean ± standard 20 
deviation). A series of median filtered curves of the AKU group indicates an abrupt increase around 21 
35-40 years of age. 22 
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Based on the effect of median filtering, individual regressions over (a) age<35 and (b) age>40 were 1 
fitted to the patient data and showed no significant variation with age. An appropriate sigmoid curve 2 
was fitted to the data (“R P”, 2014) using starting and ending values from the regressions at the end 3 
of (a) and at the start of (b) respectively. The fitted curve showed a discontinuity with its 50% point 4 
around age 37, providing support for the conjecture suggested by the median filtering. Adjusting the 5 
start and end of the respective regressions to 37 years and making minor adjustments to the start and 6 
end values of the sigmoid curve from the revised regressions produced an almost identical sigmoid 7 
curve (Figure 2) which was used to model the change of gait deviation as a function of age in our AKU 8 
sample. 9 
 10 
 11 
Figure 2: Subsets of AKU patients with and without joint replacement and with and without nitisinone 12 
treatment shown against controls. A sigmoid curve fitted on the AKU group confirmed the discontinuity 13 
of gait deviation around 37 years of age. 14 
 15 
 16 
All AKU patients under 37 years show some level of gait deviation as their MDPmean values are greater 17 
than the mean of controls. The majority of AKU patients over 37 years (28 out of 30) demonstrated 18 
more gait deviations than the mean+1SD of controls (1.88), but only 23 out of 30 were above the 95% 19 
confidence interval of the control group (2.159). 20 
 21 
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Only patients above 47 years had joint replacements (red empty and filled triangles in Figure 1) and 1 
their gait deviation was greater (2.70±0.47, N=14) than that of patients without joint replacements 2 
(2.24±0.4, N=25, red empty and filled circles in Figure 1). There are 8 AKU patients in the age range 3 
37-47 years without joint replacements but considerable deviations from normal gait. 4 
 5 
In an attempt to clarify the association of gait deviations with nitisinone treatment and joint 6 
replacements, the MDPmean of sub-groups of AKU patients were plotted in Figure 3. While clear cause-7 
effect mechanisms cannot be established without longitudinal data of individual patients, 8 
nevertheless the comparisons of sub-groups revealed some interesting findings. The 19 patients under 9 
nitisinone treatment showed higher deviations of gait from normality than the 20 patients without 10 
nitisinone treatment. Similarly, the gait of 14 patients with knee or hip joint replacements is further 11 
away from normality than those 25 without any joint replacements. Comparing the effects of knee 12 
and/or hip replacement on gait normality showed negligible differences. Nine AKU patients had a 13 
single knee replacement and an additional five had hip and knee replacements. 14 
 15 
 16 
Figure 3: A comparison of subsets of AKU patients (group means and SD with the size of group indicated 17 
on each bar). Untreated (no nitisinone, no joint replacement), Nitisinone (on nitisinone with or without 18 
joint replacement), NoJR (no joint replacement, with or without nitisinone), KHJR (knee or hip joint 19 
replacement, with or without nitisinone), KJR (knee joint replacement only, with or without nitisinone) 20 
and HJR (hip joint replacement, all 5 with knee replacement, with and without nitisinone). 21 
 22 
 23 
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Discussion 1 
 2 
An objective measure of gait function, the MDPmean, showed a pattern of deterioration in alkaptonuria 3 
similar to other indices of disease severity (Ranganath and Cox, 2011). Our data suggests a non-linear 4 
deterioration of gait function in the second half of the 4th decade which differs somewhat from the 5 
findings of Ranganath and Cox (2011) who described a gradual change in the 3rd decade followed by 6 
an accelerated progression of the disease in the 5th and 6th decades of life using clinical measures and 7 
patient questionnaires. Considering that AKU is an ultra-rare disease, gait related measures of 39 8 
patients can be regarded as a large pool of data but certainly this particular sample of patients might 9 
have influenced the fit therefore caution is advisable with setting a firm age threshold. Although the 10 
regression line in the AKU group over 37 years has a low slope (0.0026 units of MDPmean/year) 11 
indicating minimal change as a function of age, there are considerable inter-individual differences in 12 
their gait deviations. An interaction of several factors which may influence gait function (causing gait 13 
variability) justifies individualised clinical assessment for patients in this group in order to identify their 14 
specific problems which can then be targeted with appropriate treatment. 15 
 16 
Adults with AKU under 37 years of age show some movement deviations although their MDPmean is 17 
only one standard deviation away from normality. Our youngest patient was 20 years of age and so 18 
we have no information about the gait function of even younger patients and children with AKU. Early 19 
detection of movement problems may trigger focused management in order to prevent cumulative 20 
deterioration. Especially in case of children, treatment with nitisinone may have to be delayed to 21 
prevent any potential side effects (Bendadi et al. 2014). Evidence of gait deviations in the young would 22 
support earlier intervention (either nitisinone or alternatives e.g. physiotherapy), and conversely a 23 
lack of movement problems would support delaying nitisinone treatment to a later time when the 24 
chance of side effects is minimal. 25 
 26 
Adults older than 37 years of age with AKU show more deviation from normal gait than the younger 27 
group. Nevertheless if our method based on the MDPmean was used to decide if a patient moved away 28 
from normality, then the sensitivity/specificity would likely be low with false positives given that 23% 29 
of AKU patients fall within the 95% confidence interval of the control group. Further evaluation of the 30 
MDPmean as a method to separate a patient with AKU from controls is necessary using a larger sample. 31 
 32 
Patients with AKU and joint replacements were all above 47 years and their gait deviations were higher 33 
than those of the group without joint replacements. The higher age of this group likely reflects clinical 34 
11 
 
decisions of when a joint replacement is indicated. Gait does not easily return to normality; in 1 
osteoarthritis, gait was shown not to return to normal until about 11 months after total hip 2 
arthroplasty (Beaulieu et al. 2010). Potential mechanisms underlying slow recovery are: unnecessary 3 
but continued pain avoidance strategies and persistent muscle weakness due to disuse, both of which 4 
may hinder not only the affected but the contralateral side too. Persisting gait abnormality following 5 
joint replacement in AKU is likely to be due to the systemic nature of the disease which affects 6 
anatomical structures beyond the joint itself. AKU potentially affects all joints including their related 7 
ligaments, tendons and muscles and this might explain why repairing a single joint may not lead to a 8 
rapid recovery. 9 
  10 
Deviation of controls from normality, as measured by the MDPmean, shows minimal increase as a 11 
function of age. This might be explained by the self-organising neural network’s method of operation 12 
underlying the MDP method. Subsequent to defining an internal model of gait normality based on the 13 
gait of controls, the deviation from the closest matching variant of normal gait is calculated (Barton et 14 
al. 2012). As the control group included older individuals (40, 46, 47 and 60 years of age) the MDPmean 15 
of AKU patients could reflect the deviation from this subgroup of controls with altered gait due to their 16 
age. In order to determine if the gait of the older control sub-group affected the calculation of the 17 
MDPmean, a separate neural network model was generated by training with the younger group of 18 
controls and then calculating the MDPmean of the older control group. The similar MDP for the older 19 
control group (MDPmean = 1.82) compared to younger controls (22-28 years, MDPmean = 1.67) indicates 20 
that only minimal gait deviations occur as a result of ageing. As such the increased MDPmean of the 21 
older individuals with AKU is referenced to a rather coherent definition of gait normality regardless of 22 
age. Increased gait deviations therefore were due to genuine deterioration of gait related to AKU 23 
together with other factors like joint replacements and nitisinone treatment. More in-depth sub-24 
group analyses will be required to differentiate between these factors. 25 
 26 
A limitation of our method is that on its own the single number MDPmean can only be used to flag an 27 
increased deviation of gait from normality. This should then be followed up by establishing the specific 28 
gait problems which eventually is expected to lead to improved clinical decision making and treatment. 29 
Movement of body-attached markers was used to quantify deviation of gait but this approach can be 30 
complemented by including the forces acting on the body at each joint. Such an extension of the 31 
method may offer further advantages due to its focus on joint loading which is the ultimate cause of 32 
pain in alkaptonuria. An inevitable limitation of our study was the low number of participants and the 33 
cross-sectional nature of gait data. 34 
12 
 
 1 
 2 
Conclusions 3 
 4 
This was the first attempt to evaluate gait function in patients with alkaptonuria using a summary 5 
measure of gait deviation (the MDP). Patients with AKU showed minimally increased gait deviations 6 
between 20-37 years, followed by an accelerated increase around the second half of the 4th decade of 7 
life. The older group of patients was characterised by elevated and varied levels of gait deviation. 8 
Together with continued gait analysis of adults with AKU, evaluation of gait deviations in younger 9 
adults and children with AKU is necessary to complete and refine our understanding of disease 10 
progression moderated by the influence of interventions including joint replacements and nitisinone 11 
treatment. 12 
 13 
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